Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Payables (2023 - 2025)

Kura Oncology (KURA) has disclosed Payables for 3 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • Quarterly Payables rose 241.52% to $5.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2025, up 241.52% year-over-year, with the annual reading at $5.0 million for FY2025, 241.52% up from the prior year.
  • Payables for Q4 2025 was $5.0 million at Kura Oncology, down from $66.8 million in the prior quarter.
  • The five-year high for Payables was $66.8 million in Q3 2025, with the low at $1.5 million in Q4 2024.
  • Average Payables over 3 years is $15.2 million, with a median of $4.0 million recorded in 2023.
  • Peak annual rise in Payables hit 2121.82% in 2025, while the deepest fall reached 38.77% in 2025.
  • Over 3 years, Payables stood at $2.3 million in 2023, then tumbled by 36.13% to $1.5 million in 2024, then surged by 241.52% to $5.0 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $5.0 million, $66.8 million, and $52.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.